Acquired EpiVax, Inc., a bioanalytical CRO specializing in immunogenicity risk assessment, as a new platform investment.
EpiVax is a biotechnology company specializing in immunogenicity assessment, providing in silico tools and lab services for therapeutic and vaccine development
EpiVax is a biotechnology company specializing in immunogenicity assessment, providing in silico tools and lab services for therapeutic and vaccine development. The company focuses on T cell epitope prediction and immune modulation, helping clients navigate the complexities of biologics and vaccine programs.